Tech Company Financing Transactions
EydisBio Funding Round
National Institutes of Health invested in a $2.6 million funding round for EydisBio. The round was announced by the company on 8/28/2024.
Transaction Overview
Company Name
Announced On
8/28/2024
Transaction Type
Debt
Amount
$2,600,000
Round
Undisclosed
Investors
Proceeds Purpose
This grant will further support EydisBio's ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis and declare a lead compound for progression into the clinic.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
201 W. Main Street 317
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our mission is to leverage our unique platform technology and expertise to discover and develop novel small molecule therapies aimed at addressing serious unmet medical needs for patients suffering from autoimmune and inflammatory diseases. EydisBio is the first group to develop a highly selective, orally bioavailable TAK1 inhibitor for the treatment of autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Timothy Haystead
Vice President
Philip Hughes
VP - Bus. Development
Robert Freeze
VP - R & D
Scott Scarneo
Browse more venture capital transactions:
Prev: 8/28/2024: Seat Unique venture capital transaction
Next: 8/28/2024: Apricus Generation venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs